AP Interview: India could resume vaccine exports by June

Full Screen
1 / 6

Copyright 2021 The Associated Press. All rights reserved.

FILE - In this Monday, March 1, 2021, file photo, a health worker displays the AstraZeneca COVID-19 vaccine, manufactured by the Serum Institute of India before administering it to an elderly person in Gauhati, India. The world's largest vaccine maker, based in India, will be able to restart exports of AstraZeneca doses by June if new coronavirus infections subside in the country, its chief executive said Tuesday, April 6. India initially immunized the most vulnerable, but broadened that to everyone over 45 on April 1 because of the surge in cases. The resulting increased demand forced the halt in exports. (AP Photo/Anupam Nath)

NEW DELHI – The world's largest vaccine maker, based in India, will be able to restart exports of AstraZeneca doses by June if new coronavirus infections subside in the country, its chief executive said Tuesday.

But a continued surge could result in more delays because the Serum Institute of India would have to meet domestic needs, Adar Poonawalla warned in an interview with The Associated Press.

The company is a key supplier for the U.N.-backed COVAX program that aims to distribute vaccines equitably in the world. On March 25, COVAX announced a major setback in its vaccine rollout because a surge in infections in India caused the Serum Institute of India to cater to domestic demand, resulting in a delay in global shipments of up to 90 million doses.

Since then, daily new infections in India have almost doubled, with the biggest single-day spike of over 100,000 new cases on Monday. Infections are being reported faster in India than anywhere else in the world, prompting tougher virus restrictions in New Delhi and the nation's financial capital, Mumbai.

India initially immunized the most vulnerable, but broadened that to anyone over 45 on April 1 because of the surge in cases. The resulting increased demand forced the halt in exports. Since then, several top state officials have urged the federal government to further expand vaccinations.

Poonawalla said the company has “chosen to prioritize India temporarily for two months” and hopes to then restart exports.

If India's surge in infections doesn't subside, "I am scared of what ... we will have to do, and what will happen,” he said. “We are going to have to keep supplying to India, and not anywhere else. Because we have to protect our nation.”

He acknowledged that has put a “strain on our contractual obligations” to provide vaccines to other countries, and that he has been fielding phone calls from various heads of state.